Catalyst
Slingshot members are tracking this event:
European Commission Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALXN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 01, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Paroxysmal Nocturnal Hemoglobinuria, Alxn1210, Orphan Drug Designation, Atypical Hemolytic Uremic Syndrome, Myelodysplastic Syndromes
